Alphaton Capital CORP (ATON) — SEC Filings

Q: What are the key financial highlights for Alphaton Capital CORP?

Key financial highlights for Alphaton Capital CORP are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Alphaton Capital CORP?

Key executives at Alphaton Capital CORP are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Alphaton Capital CORP stock?

Risk factors for Alphaton Capital CORP (ATON) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Alphaton Capital CORP?

Forward-looking statements and predictions from Alphaton Capital CORP are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Alphaton Capital CORP. Recent 6-K filing on Dec 31, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Alphaton Capital CORP on SEC EDGAR

Overview

Alphaton Capital CORP (ATON) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 31, 2025: AlphaTON Capital Corp, formerly known as Portage Biotech Inc. and Bontan Corp Inc., filed a Form 6-K on December 31, 2025. The company, incorporated in D8 with its principal executive office in Tortola, British Virgin Islands, operates in the Finance Services sector. This filing is for the month of

Sentiment Summary

Across 44 filings, the sentiment breakdown is: 1 bearish, 43 neutral. The dominant filing sentiment for Alphaton Capital CORP is neutral.

Filing Type Overview

Alphaton Capital CORP (ATON) has filed 39 6-K, 2 20-F, 1 SC 13G/A, 1 SC 13D/A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (44)

AlphaTON Capital Corp Files 6-K — 6-K · Dec 31, 2025 Risk: low
AlphaTON Capital Corp, formerly known as Portage Biotech Inc. and Bontan Corp Inc., filed a Form 6-K on December 31, 2025. The company, incorporated in D8 with
6-K Filing — 6-K · Dec 23, 2025
6-K Filing — 6-K · Nov 26, 2025
6-K Filing — 6-K · Nov 21, 2025
AlphaTON Capital Corp Files 6-K Report — 6-K · Oct 23, 2025 Risk: low
AlphaTON Capital Corp, formerly Portage Biotech Inc., filed a Form 6-K on October 23, 2025. The company, incorporated in D8 and headquartered in Tortola, Britis
AlphaTON Capital Corp Files 6-K Report — 6-K · Oct 22, 2025 Risk: low
AlphaTON Capital Corp, formerly known as Portage Biotech Inc., filed a Form 6-K on October 22, 2025. The company, incorporated in D8 and headquartered in Tortol
AlphaTON Capital Corp Files 6-K Report — 6-K · Sep 25, 2025 Risk: low
AlphaTON Capital Corp, formerly Portage Biotech Inc., filed a Form 6-K on September 25, 2025. The company, which operates in the Pharmaceutical Preparations sec
AlphaTON Capital Corp Files 6-K Report — 6-K · Sep 23, 2025 Risk: low
AlphaTON Capital Corp, formerly Portage Biotech Inc., filed a Form 6-K on September 23, 2025, reporting for the month of September 2025. The company, based in T
AlphaTON Capital Corp Files 6-K Report — 6-K · Sep 4, 2025 Risk: low
AlphaTON Capital Corp, formerly Portage Biotech Inc., filed a Form 6-K on September 4, 2025. The company, incorporated in the British Virgin Islands, is in the
Portage Biotech Files September 2025 6-K Report — 6-K · Sep 3, 2025 Risk: low
Portage Biotech Inc. filed a Form 6-K on September 3, 2025, reporting for the month of September 2025. The company, previously known as AlphaTON Capital Corp, i
Portage Biotech Navigates Equity Shifts Amidst Pre-Revenue Phase — 20-F · Jul 25, 2025 Risk: high
PORTAGE BIOTECH INC. (ATON) reported no revenue for the fiscal year ended March 31, 2025, consistent with its pre-revenue biotechnology status. The company's ne
Portage Biotech Files 6-K Report — 6-K · Jun 27, 2025 Risk: low
Portage Biotech Inc. filed a Form 6-K on June 27, 2025, for the month of June 2025. The filing is a Report of Foreign Private Issuer and is incorporated by refe
Portage Biotech Files June 2025 6-K Report — 6-K · Jun 25, 2025 Risk: low
Portage Biotech Inc. filed a Form 6-K on June 25, 2025, reporting for the month of June 2025. The company, previously known as Bontain Corp Inc. and Dealcheck C
Portage Biotech Inc. Files June 2025 6-K Report — 6-K · Jun 9, 2025 Risk: low
Portage Biotech Inc. filed a Form 6-K on June 9, 2025, reporting for the month of June 2025. The company, incorporated in the British Virgin Islands, is a pharm
Portage Biotech Inc. Files 6-K Report — 6-K · May 29, 2025 Risk: low
Portage Biotech Inc. filed a Form 6-K on May 29, 2025, to report on events for the month of May 2025. The filing indicates that this report is incorporated by r
Portage Biotech Files 6-K Report — 6-K · Apr 28, 2025 Risk: low
Portage Biotech Inc. filed a Form 6-K on April 28, 2025, for the month of April 2025. The filing is a Report of Foreign Private Issuer and is incorporated by re
Portage Biotech Inc. Files March 2025 6-K Report — 6-K · Mar 27, 2025 Risk: low
Portage Biotech Inc. filed a Form 6-K on March 27, 2025, reporting for the month of March 2025. The company, previously known as Bontain Corp Inc. and Dealcheck
Portage Biotech Files March 2025 6-K Report — 6-K · Mar 13, 2025 Risk: low
Portage Biotech Inc. filed a Form 6-K on March 13, 2025, to report its activities for the month of March 2025. The filing is a report of a foreign private issue
Portage Biotech Files 6-K, Incorporates into S-8 — 6-K · Mar 12, 2025 Risk: low
Portage Biotech Inc. filed a Form 6-K on March 12, 2025, to report information for the month of March 2025. The filing is incorporated by reference into their F
Portage Biotech Files 6-K, Incorporates into S-8 — 6-K · Feb 12, 2025 Risk: low
Portage Biotech Inc. filed a Form 6-K on February 12, 2025, to report information for the month of February 2025. The filing is incorporated by reference into t
Portage Biotech Files January 2025 6-K Report — 6-K · Jan 30, 2025 Risk: low
Portage Biotech Inc. filed a Form 6-K on January 30, 2025, reporting for the month of January 2025. The company is incorporated in the British Virgin Islands an
Portage Biotech Inc. Files Form 6-K for Registration Statement — 6-K · Jan 6, 2025 Risk: low
Portage Biotech Inc. filed a Form 6-K on January 6, 2025, to be incorporated by reference into its Form S-8 registration statement (File No. 333-275842). The co
Portage Biotech Files 6-K, Incorporates into S-8 — 6-K · Dec 17, 2024 Risk: low
Portage Biotech Inc. filed a Form 6-K on December 17, 2024, reporting for the month of December 2024. The company is incorporated in the British Virgin Islands
Portage Biotech Inc. Files 6-K Report — 6-K · Dec 13, 2024 Risk: low
Portage Biotech Inc. filed a Form 6-K on December 13, 2024, to report information for the month of December 2024. The filing is incorporated by reference into i
Portage Biotech Inc. Files 6-K Report — 6-K · Dec 12, 2024 Risk: low
Portage Biotech Inc. filed a Form 6-K on December 12, 2024, reporting as a foreign private issuer. The company, incorporated in the British Virgin Islands, prev
Portage Biotech Files 6-K, Incorporates by Reference — 6-K · Dec 5, 2024 Risk: low
Portage Biotech Inc. filed a Form 6-K on December 5, 2024, to report information for the month of December 2024. The filing indicates that this report is incorp
Portage Biotech Inc. Files Form 6-K — 6-K · Nov 26, 2024 Risk: low
Portage Biotech Inc. filed a Form 6-K on November 26, 2024, reporting for the month of November 2024. The company, incorporated in the British Virgin Islands, i
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
Bailey Amends Portage Biotech Stake Filing — SC 13D/A · Nov 14, 2024 Risk: medium
Dr. Gregory H. Bailey, through an amendment filed on November 14, 2024, has updated his Schedule 13D filing for Portage Biotech Inc. The filing indicates a chan
Portage Biotech Files 6-K, Incorporates into S-8 — 6-K · Oct 4, 2024 Risk: low
Portage Biotech Inc. filed a Form 6-K on October 4, 2024, to report information for the month of October 2024. The filing is incorporated by reference into the
Portage Biotech Files 6-K, Incorporates S-8 Registration — 6-K · Sep 4, 2024 Risk: low
Portage Biotech Inc. filed a Form 6-K on September 4, 2024, to report for the month of September 2024. The filing indicates that the company is a foreign privat
Portage Biotech Inc. Files Form 6-K — 6-K · Aug 27, 2024 Risk: low
Portage Biotech Inc. filed a Form 6-K on August 27, 2024, for the month of August 2024. The filing is a report of a foreign private issuer and is incorporated b
Portage Biotech Inc. Files Routine 6-K Report — 6-K · Aug 15, 2024 Risk: low
Portage Biotech Inc. filed a Form 6-K on August 15, 2024, reporting its status as a foreign private issuer. The company, incorporated in the British Virgin Isla
Portage Biotech Files 20-F Annual Report — 20-F · Aug 14, 2024 Risk: medium
Portage Biotech Inc. filed its annual report on Form 20-F for the fiscal year ending March 31, 2024. The company, incorporated in the British Virgin Islands, op
Portage Biotech Inc. Files August 2024 6-K Report — 6-K · Aug 13, 2024 Risk: low
Portage Biotech Inc. filed a Form 6-K on August 13, 2024, reporting for the month of August 2024. The company is incorporated in the British Virgin Islands and
Portage Biotech Files 6-K for April 2024 — 6-K · May 1, 2024 Risk: low
Portage Biotech Inc. filed a Form 6-K on May 1, 2024, for the month ending April 30, 2024. The company, incorporated in the British Virgin Islands, is a pharmac
Portage Biotech Inc. Files April 2024 6-K Report — 6-K · Apr 12, 2024 Risk: low
Portage Biotech Inc. filed a Form 6-K on April 12, 2024, reporting for the month of April 2024. The company, incorporated in the British Virgin Islands, is a ph
Portage Biotech Files Form 6-K — 6-K · Mar 8, 2024 Risk: low
Portage Biotech Inc. filed a Form 6-K on March 8, 2024, to report information for the month of March 2024. The company is incorporated in the British Virgin Isl
Portage Biotech Inc. Files March 2024 6-K Report — 6-K · Mar 7, 2024 Risk: low
Portage Biotech Inc. filed a Form 6-K on March 7, 2024, reporting for the month of March 2024. The company, incorporated in the British Virgin Islands, has its
Portage Biotech Files 6-K, Confirms Foreign Private Issuer Status — 6-K · Feb 29, 2024 Risk: low
Portage Biotech Inc. (NASDAQ: PRTG) filed a Form 6-K on February 29, 2024, for the month of February 2024, indicating its status as a foreign private issuer. Th
Portage Biotech Files 6-K, Confirms Foreign Private Issuer Status — 6-K · Feb 28, 2024 Risk: low
Portage Biotech Inc. filed a Form 6-K with the SEC on February 28, 2024, for the month of February 2024, indicating its status as a foreign private issuer. The
SC 13G Filing — SC 13G · Feb 14, 2024
Portage Biotech Files 6-K, Updates Corporate Presentation — 6-K · Jan 18, 2024
Portage Biotech Inc. filed a 6-K on January 18, 2024, primarily to furnish its latest Corporate Presentation as Exhibit 99.1. This filing indicates that the com
Portage Biotech 6-K Links Press Release to Key Filings — 6-K · Jan 4, 2024
Portage Biotech Inc., a British Virgin Islands-based pharmaceutical company, filed a 6-K on January 4, 2024, indicating it is a foreign private issuer. This fil

Risk Profile

Risk Assessment: Of ATON's 37 recent filings, 1 were flagged as high-risk, 2 as medium-risk, and 34 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

Ian Walters
Dr. Gregory H. Bailey
Bailey Gregory

Top Tags

foreign-private-issuer (21) · sec-filing (16) · reporting (13) · regulatory-filing (11) · 6-K (8) · registration-statement (6) · foreign-issuer (6) · 6-k (4) · filing (3) · company-name-change (2)

Key Numbers

Filing Date: 20251231 — Indicates the report was filed as of December 31, 2025.
Period of Report: 20251230 — The report covers activities up to December 30, 2025.
SEC File Number: 001-40086 — Identifies the company's registration with the SEC.
Public Documents: 2 — Number of documents included in the filing
Revenue: $0 — Reported for the fiscal year ended March 31, 2025, indicating pre-revenue status.
Fiscal Year End: 2025-03-31 — The period covered by this 20-F filing.
SIC Code: 2834 — Standard Industrial Classification for Pharmaceutical Preparations, defining the company's industry.
Form S-8 File Number: 333-275842 — This filing is incorporated by reference into this registration statement.
Reporting Period: March 2025 — The period covered by this Form 6-K filing.
Fiscal Year Start: 2023-04-01 — The start date for the reporting period covered by the 20-F.
Report Period End Date: 20240430 — Indicates the end of the reporting period for this 6-K filing.

Related Companies

PTGE · PORT · PRTG

Frequently Asked Questions

What are the latest SEC filings for Alphaton Capital CORP (ATON)?

Alphaton Capital CORP has 44 recent SEC filings from Jan 2024 to Dec 2025, including 39 6-K, 2 20-F, 1 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of ATON filings?

Across 44 filings, the sentiment breakdown is: 1 bearish, 43 neutral. The dominant sentiment is neutral.

Where can I find Alphaton Capital CORP SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Alphaton Capital CORP (ATON) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Alphaton Capital CORP?

Financial highlights for Alphaton Capital CORP are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for ATON?

The investment thesis for ATON includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Alphaton Capital CORP?

Key executives identified across Alphaton Capital CORP's filings include Ian Walters, Dr. Gregory H. Bailey, Bailey Gregory.

What are the main risk factors for Alphaton Capital CORP stock?

Of ATON's 37 assessed filings, 1 were flagged high-risk, 2 medium-risk, and 34 low-risk.

What are recent predictions and forward guidance from Alphaton Capital CORP?

Forward guidance and predictions for Alphaton Capital CORP are extracted from SEC filings as they are enriched.